Tag:
Lundbeck
Latest Headlines
Latest Headlines
Lundbeck soars on PhIII success for blockbuster hopeful
Lundbeck shares spiked 9% this morning on the news that three late-stage studies of its new depression drug had delivered the data needed to support upcoming regulatory filings.
Lundbeck banks on pipeline as antidepressant sales skid
Lundbeck's CFO Anders Gotzsche emphasized the prospects of drugs such as Selincro for alcohol dependence, the experimental antidepressant Lu AA21004 in late-stage development and a long-lasting formulation of Abilify.
Lundbeckfond contributes to $25M B round for AlloCure's Phase II stem cell study
Lundbeckfond Ventures has stepped in to lead a $25 million venture round for AlloCure, a Burlington, MA-based stem cell company.
PhIII placebo response complicates Lundbeck's case for anti-drinking drug
Lundbeck has taken the wraps off its Phase III data for the alcohol dependence drug nalmefene.
Novartis, Lundbeck score wins for manufacturing in the West
Kudos to the Novartis ( $NVS ) ops team in Nyon, Switzerland! They've persuaded execs to keep open an OTC drug-making plant that the company had doomed to closure last fall. The company also has agreed
Lean earns Lundbeck big prize, cost cuts
Lundbeck has succeeded in cutting production costs by 25% for products made in-house. The savings are relative to 2006, when it began practicing lean production principles, the company said in an...
Docs demand Hospira action on execution drug
An international group of doctors is putting the squeeze on Hospira ( $HSP ) over a drug now being used for executions by U.S. death-penalty states. Writing in The Lancet, 25 physicians said Hospira
Lundbeck files app for alcohol dependence drug
Lundbeck has filed for European approval of Selincro, a new treatment for alcohol dependence. The Dutch company obtained the treatment in a 96 million euro licensing deal with Biotie . New late-stage
FDA accepts Otsuka's app for long-lasting Abilify
Otsuka Pharmaceutical has taken an important step forward in the development of a once-monthly version of its blockbuster schizophrenia drug Abilify (aripiprazole). U.S. regulators have accepted for...
Lundbeck makes $200M down payment in blockbuster CNS drug pact with Otsuka
Danish drugmaker Lundbeck and Japanese drug giant Otsuka have joined forces for a pact that makes the two companies major partners in the global market for drugs against diseases of the central
